Cargando…

Blunted cardiovascular effects of beta-blockers in patients with cirrhosis: Relation to severity?

AIMS: Patients with cirrhosis and portal hypertension are at high risk of developing complications such as variceal hemorrhage, ascites, and cardiac dysfunction, the latter of which is known as cirrhotic cardiomyopathy. Since non-selective beta-blockers (NSBB) may aggravate hemodynamic complications...

Descripción completa

Detalles Bibliográficos
Autores principales:	Nabilou, Puria, Danielsen, Karen Vagner, Kimer, Nina, Hove, Jens Dahlgaard, Bendtsen, Flemming, Møller, Søren
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Public Library of Science 2022
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9239488/ https://www.ncbi.nlm.nih.gov/pubmed/35763518 http://dx.doi.org/10.1371/journal.pone.0270603

Ejemplares similares

Markers of inflammation predict survival in newly diagnosed cirrhosis: a prospective registry study
por: Mynster Kronborg, Thit, et al.
Publicado: (2023)

Nurse-assisted and multidisciplinary outpatient follow-up among patients with decompensated liver cirrhosis: A systematic review
por: O’Connell, Malene Barfod, et al.
Publicado: (2023)

No effect of rifaximin on soluble CD163, mannose receptor or type III and IV neoepitope collagen markers in decompensated cirrhosis: Results from a randomized, placebo controlled trial
por: Kimer, Nina, et al.
Publicado: (2018)

Atorvastatin for patients with cirrhosis. A randomized, placebo-controlled trial
por: Kronborg, Thit M., et al.
Publicado: (2023)

Cardiac Function in Patients with Early Cirrhosis during Maximal Beta-Adrenergic Drive: A Dobutamine Stress Study
por: Krag, Aleksander, et al.
Publicado: (2014)

Atorvastatin for prevention of disease progression and hospitalisation in liver cirrhosis: protocol for a randomised, double-blind, placebo-controlled trial
por: Kimer, Nina, et al.
Publicado: (2020)

Beta-blockers in liver cirrhosis
por: Giannelli, Valerio, et al.
Publicado: (2014)

Novel Anti-inflammatory Treatments in Cirrhosis. A Literature-Based Study
por: Kronborg, Thit Mynster, et al.
Publicado: (2021)

Beta-blockers in cirrhosis: Evidence-based indications and limitations
por: Rodrigues, Susana G., et al.
Publicado: (2019)

Beta-blockers in patients with liver cirrhosis: Pragmatism or perfection?
por: Sauerbruch, Tilman, et al.
Publicado: (2023)

Postprandial Increase in Mesenteric Blood Flow is Attenuated in Parkinson’s Disease: A Dynamic PC-MRI Study
por: Siebner, Thomas Hartwig, et al.
Publicado: (2021)

The impact of rifaximin on inflammation and metabolism in alcoholic hepatitis: A randomized clinical trial
por: Kimer, Nina, et al.
Publicado: (2022)

Differential inflammasome activation predisposes to acute-on-chronic liver failure in human and experimental cirrhosis with and without previous decompensation
por: Monteiro, Sofia, et al.
Publicado: (2021)

Tunneled Peritoneal Catheter for Refractory Ascites in Cirrhosis: A Randomized Case-Series
por: Kimer, Nina, et al.
Publicado: (2020)

The Potential Anti-remodeling Effect of Paroxetine After Myocardial Infarction May Be Blunted by Beta-Blockers
por: Iborra-Egea, Oriol, et al.
Publicado: (2022)

Gastric Emptying Is Not Delayed and Does Not Correlate With Attenuated Postprandial Blood Flow Increase in Medicated Patients With Early Parkinson's Disease
por: Siebner, Thomas Hartwig, et al.
Publicado: (2022)

Nonselective beta-blocker use is associated with increased hepatic encephalopathy-related readmissions in cirrhosis
por: Fallahzadeh, Mohammad Amin, et al.
Publicado: (2022)

Heart Rate and Cardiovascular Disease: An Alternative to Beta Blockers
por: Liang, Michael, et al.
Publicado: (2009)

Changes in weight, body composition and metabolic parameters after switch to dolutegravir/lamivudine compared with continued treatment with dolutegravir/abacavir/lamivudine for virologically suppressed HIV infection (The AVERTAS trial): a randomised, open-label, superiority trial in Copenhagen, Denmark
por: Pedersen, Karen Brorup Heje, et al.
Publicado: (2023)

Non-selective beta-blockers and the incidence of hepatocellular carcinoma in patients with cirrhosis: a meta-analysis
por: He, Xinyi, et al.
Publicado: (2023)

Treatment with non‐selective beta‐blockers affects the systemic inflammatory response to bacterial DNA in patients with cirrhosis
por: Gimenez, Paula, et al.
Publicado: (2018)

Beta‐blockers for hypertension
por: Wiysonge, Charles S, et al.
Publicado: (2017)

Beta-blockers in sepsis
por: Singer, Mervyn
Publicado: (2019)

Beta Blockers and Melanoma
por: Vojvodic, Aleksandra, et al.
Publicado: (2019)

Collagen type IV remodelling gender‐specifically predicts mortality in decompensated cirrhosis
por: Lehmann, Jennifer, et al.
Publicado: (2019)

The Combination of Beta-Blockers and ACE Inhibitors Across the Spectrum of Cardiovascular Diseases
por: Strauss, Martin H., et al.
Publicado: (2021)

An unusual toxicity with beta blocker and calcium channel blocker
por: Anand, Vijay, et al.
Publicado: (2015)

D-53 | Impact of Cardiovascular Diseases, Calcium Channel Blockers and Beta-Blockers on Mortality of Patients Hospitalized with COVID-19
por: Alhusain, Rashid, et al.
Publicado: (2022)

Acute decompensation boosts hepatic collagen type III deposition and deteriorates experimental and human cirrhosis
por: Praktiknjo, Michael, et al.
Publicado: (2018)

Perioperative use of beta-blockers
por: Priebe, Hans-Joachim
Publicado: (2009)

Effectiveness and safety of concurrent beta-blockers and inhaled bronchodilators in COPD with cardiovascular comorbidities
por: Corrao, Salvatore, et al.
Publicado: (2017)

Non-selective beta blocker use is associated with improved short-term survival in patients with cirrhosis referred for liver transplantation
por: Ngwa, Taiwo, et al.
Publicado: (2020)

Association Between Nonselective Beta-Blocker Use and Hepatocellular Carcinoma in Patients With Chronic Hepatitis B Without Cirrhosis and Decompensation
por: Cheng, He-Yun, et al.
Publicado: (2022)

Non-Selective Beta-Blockers and Risk of Sepsis in Patients with Cirrhosis and Ascites: Results from a Large Observational Study
por: Jensen, Morten Daniel, et al.
Publicado: (2023)

Calcium-Channel Blockers: An Alternative Therapy to Beta-Blockers for Myocardial Infarction?
por: Hao, Kiyotaka, et al.
Publicado: (2023)

Beta-blockers use in patients with chronic obstructive pulmonary disease and concomitant cardiovascular conditions
por: Albouaini, Khaled, et al.
Publicado: (2007)

Prediction of Major Depressive Disorder Following Beta-Blocker Therapy in Patients with Cardiovascular Diseases
por: Jin, Suho, et al.
Publicado: (2020)

Association of beta-blockers beyond 1 year after myocardial infarction and cardiovascular outcomes
por: Ishak, Divan, et al.
Publicado: (2023)

Suboptimal diagnostic accuracy of ultrasound and CT for compensated cirrhosis: Evidence from prospective cohort studies
por: Hetland, Liv E., et al.
Publicado: (2023)

Nonselective beta-blockers may lead to stage 2 acute kidney injury and waitlist mortality in child class C cirrhosis
por: Lai, Mason, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_lsn679lreom5taehqsu7jadvm1